Drug Profile
ZV Combi
Latest Information Update: 17 Oct 2018
Price :
$50
*
At a glance
- Originator LG Life Sciences
- Developer LG Chem
- Class Antihypertensives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hypertension
Most Recent Events
- 17 Oct 2018 No development reported - Phase-II for Hypertension in China (unspecified route)
- 28 Aug 2015 Phase-II clinical trials in Hypertension in China (unspecified route)